Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, reports recent findings from a study using pembrolizumab and lenvatinib as a second-line treatment for clear cell…
Suresh Ramalingam, MD, FASCO, deputy director, Winship Cancer Institute of Emory University, addresses autoimmune toxicities associated with combination immune therapies as in the CheckMate-227 trial for non-small cell…
Joshua K. Sabari, MD, assistant professor in the Department of Medicine at NYU Langone Health’s Perlmutter Cancer Center, addresses the need for additional predictive biomarkers for non-small cell…
Christian U. Blank, MD, PhD, medical oncologist in the Division of Immunology at the Netherlands Cancer Institute, provides a three year update for the first clinical trial for the…
Martin Fischer, PhD, associate research professor in the department of chemistry at Duke Trinity College of Arts and Sciences, was tasked with examining the particle-blocking abilities of various…
Guidelines from the American Society of Hematology (ASH) review panel recommend standards of care for individualized acute myeloid leukemia (AML) treatments. For patients with newly diagnosed AML, ASH…
Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses barriers to achieving racially diverse clinical trials for…
The American Society of Hematology (ASH) has released 2020 guidelines for treating newly diagnosed acute myeloid leukemia (AML) in older adults. Specifically, the guidelines help patients and doctors…
Mark A. Socinski, MD, executive medical director at AdventHealth Cancer Institute, recommends immediate comprehensive molecular testing at the time of lung cancer diagnosis. Stating that oncogenic driver mutation…
Carlos Del Rio, MD, Executive Associate Dean at Emory School of Medicine & Grady Health System, breaks down the four phases of clinical trials and discusses how the…
